Repros Therapeutics Inc. (RPRX) Social Stream
ROYALTY PHARMA PLC (RPRX) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering RPRX.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-10 | 8 | $56.001 | $46 | $51.714 | $43.45 | 19.02% |
| 2022-02-02 | 7 | $56 | $46 | $51.714 | $43.45 | 19.02% |
| 2022-03-08 | 7 | $56 | $46 | $51.142 | $43.45 | 17.7% |
| 2022-04-06 | 7 | $56 | $48 | $51.428 | $43.45 | 18.36% |
| 2022-05-06 | 7 | $56 | $48 | $51.428 | $43.45 | 18.36% |
| 2022-06-09 | 9 | $56 | $48 | $52.111 | $43.45 | 19.93% |
| 2022-06-14 | 10 | $56 | $47 | $51.6 | $43.45 | 18.76% |
| 2022-08-03 | 10 | $57 | $47 | $52.3 | $43.45 | 20.37% |
| 2022-08-19 | 10 | $57 | $47 | $52.6 | $43.45 | 21.06% |
The Trend in the Analyst Price Target
Over the past 127 days, RPRX's average price target has gone up $1.17.
RPRX reports an average of 27.44% for its upside potential over the past 51 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-08-28 | 9 | 56 | 46 | 51.500 | 39.19 | 31.41% |
| 2022-03-08 | 7 | 56 | 46 | 51.142 | 37.67 | 35.76% |
| 2022-04-29 | 7 | 56 | 48 | 51.428 | 42.58 | 20.78% |
| 2022-06-09 | 9 | 56 | 48 | 52.111 | 41.08 | 26.85% |
| 2022-08-08 | 10 | 57 | 47 | 52.600 | 43.13 | 21.96% |
RPRX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.15 | 8 | 2 | 0 | 0 | 0 | 10 |
The Trend in the Broker Recommendations
RPRX's average broker recommendation rating improved by 1.13 over the prior 43 weeks.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for RPRX as an investment opportunity.
- ROYALTY PHARMA PLC's variance in analysts' estimates is lower than 10.66% of stocks in the large market cap category.
- In the context of Pharmaceutical Products stocks, ROYALTY PHARMA PLC's upside potential (average analyst target price relative to current price) is higher than 121.62% of them.
- RPRX has a higher number of analysts covering the stock than 223.73% of stocks in the large market cap category.
- In the context of stocks in the large market cap category, ROYALTY PHARMA PLC's average analyst price target is higher than 251.24% of them.
Stocks similar to ROYALTY PHARMA PLC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are REGN, RDY, and RARE.
View All Top Stocks by Price Target
Make investment decisions regarding RPRX using the data that counts. Try POWR Ratings for free.